Literature DB >> 31895118

Noninvasive positive pressure ventilation in stable patients with COPD.

Samuel P Wiles1, Loutfi S Aboussouan, Eduardo Mireles-Cabodevila.   

Abstract

PURPOSE OF REVIEW: Long-term noninvasive positive pressure ventilation (NIV) used to be a controversial form of therapy for patients with stable hypercapnic chronic obstructive pulmonary disease (SH-COPD). New evidence described in this review defines the optimal settings, timing and target population for NIV utilization in SH-COPD necessary to maximize its benefit. RECENT
FINDINGS: NIV, when titrated appropriately, leads to improved clinical outcomes. High inspiratory positive airway pressures aimed at decreasing CO2 levels can ensure NIV success in SH-COPD. NIV initiated when patients remain hypercapnic whereas in a clinical stable state following an acute exacerbation can prolong the time to a readmission. Technological advances in NIV algorithms and remote monitoring have the potential to improve use and titration. NIV and portable NIV improve exercise tolerance and may accentuate the benefits derived from pulmonary rehabilitation alone.
SUMMARY: Use of high-intensity NIV in SH-COPD is beneficial yet appropriate patient selection and implementation is paramount.

Entities:  

Mesh:

Year:  2020        PMID: 31895118     DOI: 10.1097/MCP.0000000000000657

Source DB:  PubMed          Journal:  Curr Opin Pulm Med        ISSN: 1070-5287            Impact factor:   3.155


  2 in total

1.  Efficacy of nalmefene with noninvasive positive-pressure ventilation on elderly patients with chronic obstructive pulmonary disease combining with type II respiratory failure.

Authors:  Zhen Wu; Heyan Gu; Ronghua Tian; Xia Liu
Journal:  Am J Transl Res       Date:  2021-11-15       Impact factor: 4.060

2.  Effect of Noninvasive Positive Pressure Ventilation on Prognosis and Blood Gas Level in COPD Patients Complicated with Respiratory Failure.

Authors:  Xiaoqing Xiong; Wensheng Yuan
Journal:  Evid Based Complement Alternat Med       Date:  2022-08-05       Impact factor: 2.650

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.